Several clinical studies are underway to re-purpose or expand the indication of the molecules in our portfolio.
We believe in the transformative power of medical innovation to improve human health.
We set out to establish the safety and efficacy of our products, but also to improve standards of care. Ultimately, we want to help physicians better care for their patients. Take for example our prospective study to demonstrate the benefit of early treatment of copperhead envenomation. Our research also aims to investigate the value of our products to payers and healthcare systems, such as using Medicare data to determine how one of our treatments can reduce hospital stays.
We are also excited to be exploring new uses and indications for our existing portfolio. For example, we are exploring whether DigiFab® (Digoxin Immune FAB (ovine)) could be used to prevent kidney injury in patients undergoing coronary artery bypass graft (CABG) surgery. In 2019 we were granted an Investigational New Drug application by the US FDA to explore a potential new indication for the planned use of Voraxaze® alongside high-dose methotrexate. Investigators recently published initial data from a pilot study exploring the planned use of Voraxaze® in patients with central nervous system lymphoma (CNSL).
We also have the privilege to partner with clinicians, toxicologists, and academics at top hospitals such as the Mayo Clinic, Memorial Sloan Kettering Cancer Center, and the University of Maryland Baltimore. Please see our Grant and Investigator Initiated Studies pages for more information on how you can work with BTG Specialty Pharmaceuticals.
We provide support for publication, data analysis, and fellow contributions to independent research.Read more
Investigator Initiated Studies
We support independent research that furthers the understanding of disease and their treatment.Read more
We support educational activities that are objective, balanced and scientifically rigorous.Read more